Daiichi Sankyo Receives US FDA Approval for VANFLYTA® First FLT3 Inhibitor

Daiichi Sankyo announced that VANFLYTA® (quizartinib) has received approval from the U.S. Food and Drug Administration (FDA) for a comprehensive treatment approach in adult patients with newly diagnosed acute myeloid leukaemia (AML) who test positive for FLT3-ITD as determined by an FDA-approved test.

VANFLYTA is the first and only FLT3 inhibitor approved by the FDA for FLT3-ITD positive AML across all three phases of treatment – induction, consolidation, and maintenance – for patients who do not undergo transplant. This means that patients with this specific type of AML can receive VANFLYTA throughout their treatment journey.

VANFLYTA is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML. 

The approval of VANFLYTA represents a significant advancement for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which is one of the most aggressive and difficult-to-treat subtypes.

The approval of VANFLYTA also extends to Japan, where it is approved for the treatment of AML that is FLT3-ITD mutation positive. In Japan, it is approved for use in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as maintenance monotherapy for adult patients with newly diagnosed FLT3-ITD positive AML. 

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!